Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans [Yahoo! Finance]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Yahoo! Finance
rate, 5.5-month median progression-free survival and 87% disease control in heavily pretreated, unresectable metastatic colorectal cancer, with a manageable safety profile and no significant liver toxicity. The company is leveraging these data to pursue FDA discussions on registrational trials and potential accelerated pathways, while also advancing a Biologics License Application for ozekibart in conventional chondrosarcoma after its ChonDRAgon trial met its primary endpoint. Against this backdrop, we will examine how the promising colorectal cancer efficacy signal for ozekibart shapes Inhibrx Biosciences' investment narrative. AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. What Is Inhibrx Biosciences' Investment Narrative? To own Inhibrx Biosciences, you have to believe that ozekibart can translate from promisin
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences (INBX) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue [Seeking Alpha]Seeking Alpha
- T-Mobile reportedly in merger talks, Adobe's $25B stock buyback [Yahoo! Finance Canada]Yahoo! Finance Canada
- Inhibrx cancer drug reportedly drawing interest of Merck and rivals [Seeking Alpha]Seeking Alpha
INBX
Earnings
- 8/13/25 - Beat
INBX
Sec Filings
- 4/27/26 - Form 4
- 4/23/26 - Form ARS
- 4/23/26 - Form DEF
- INBX's page on the SEC website